Snapshot · The Peter Attia Drive
Plasma desmosterol correlates highly with cerebrospinal fluid desmosterol and brain tissue cholesterol synthesis, making it a measurable blood biomarker of brain cholesterol production; low levels are associated with higher rates of cognitive impairment.
Where this was said
At 1:18:20 · chapter starts 1:17:15
Tom synthesizes the desmosterol and 24S-hydroxycholesterol threads that have run through the episode. Plasma desmosterol is commercially measurable and correlates strongly with CSF desmosterol — a published study using mass spectrometry confirmed high correlation and found that low plasma desmosterol is associated with increased rates of cognitive impairment and Alzheimer's disease [1] — Tom Dayspring "24S-hydroxycholesterol as neuronal distress marker: Elevated plasma 24S-hydroxycholesterol signals that neurons are excreting excess choles…" 1:06:40 . If a patient is on a statin and their plasma desmosterol falls too low, that could indicate over-suppression of brain cholesterol synthesis, warranting a dose reduction or switch to a non-statin ApoB-lowering strategy. 24S-hydroxycholesterol, produced when neurons need to shed excess cholesterol, is elevated in early Alzheimer's disease and falls with statin use — another marker of improved neuronal cholesterol balance. Unfortunately, 24S-hydroxycholesterol is not yet available through commercial laboratories. Tom expresses the hope that it will become a routine clinical tool, since it would allow clinicians to simultaneously confirm adequate statin effect on brain cholesterol (falling 24S-hydroxycholesterol) and absence of over-suppression (stable desmosterol).
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.